Luc Dirix

37.8k citations
311 papers · 14.7k · 3 hit papers · h-index 66

Impact in

  • Oncology top 0.1%
    • HER2/EGFR in Cancer Research
    • Cancer Immunotherapy and Biomarkers
    • Cancer Treatment and Pharmacology
    • Cancer Cells and Metastasis
    • Breast Cancer Treatment Studies
    • Cancer Genomics and Diagnostics

Papers in

    • HER2/EGFR in Cancer Research 50
    • Cancer Treatment and Pharmacology 47
    • Cancer Immunotherapy and Biomarkers 31
    • Cancer Cells and Metastasis 29
    • Advanced Breast Cancer Therapies 34

Luc Dirix

308 papers receiving 14.4k citations

Luc Dirix's Hit Papers

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study 2017 · 593 citations
5930+5+10Years since publication200400600

Peers

Luc Dirix
Comparison fields: 5 of 143
  • Oncology 7.6k
  • Cancer Research 3.6k
  • Pulmonary and Respiratory Medicine 2.6k
  • Immunology 1.2k
  • Genetics 550
Replace Joan Albanell with:
Joan Albanell Spain
Frédérique Penault‐Llorca France
Sabino De Placido Italy
Stefan Sleijfer Netherlands
Do‐Youn Oh South Korea
Naoto T. Ueno United States
Alberto Ocaña Spain
Patrice Viens France
Nobuyuki Arima Japan
Yoshitaka Fujii Japan
Luc Dirix relative to Joan Albanell Spain Joan Albanell's profile →
Citations per field
00.5×1.6×
Joan Albanell · 1×
Citations per year

Countries citing papers authored by Luc Dirix

Since Specialization
Citations

This map shows the geographic impact of Luc Dirix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luc Dirix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luc Dirix more than expected).

Fields of papers citing papers by Luc Dirix

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luc Dirix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luc Dirix. The network helps show where Luc Dirix may publish in the future.

Co-authors

The 25 scholars most cited alongside Luc Dirix, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Luc Dirix Line = papers co-authored together Luc Dirix links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 311 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Hit paper breakdown →
2010703
2
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Hit paper breakdown →
2017593
3
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Hit paper breakdown →
2017437
4 2010392
5 2007348
6 2002341
7 2010334
8 2001306
9 2013303
10 2004289
11 2000264
12
Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer.
1998243
13 2015237
14 2008230
15 2001218
16 2015197
17 2004185
18 2003172
19 2002167
20 2008166

About Luc Dirix

Luc Dirix is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Surgery, having authored 311 papers that have together received 14.7k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (50 papers), Cancer Treatment and Pharmacology (47 papers), Breast Cancer Treatment Studies (34 papers), Advanced Breast Cancer Therapies (34 papers), Cancer Immunotherapy and Biomarkers (31 papers), Cancer Cells and Metastasis (29 papers), Estrogen and related hormone effects (25 papers) and Cancer Genomics and Diagnostics (21 papers). The work is most often cited by research in Oncology (7.6k citations), Cancer Research (3.6k citations), Pulmonary and Respiratory Medicine (2.6k citations), Immunology (1.2k citations) and Genetics (550 citations). Luc Dirix has collaborated with scholars based in Belgium, United States and United Kingdom. Frequent co-authors include Steven Van Laere, Peter A. van Dam, Peter Vermeulen, Peter Vermeulen, Ilse Van der Auwera, Cécile Colpaert, Eric A. Van Marck, Gert G. Van den Eynden, Eric Van Marck and Ina Benoy. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, British Journal of Cancer and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact